2020 Revenues ($USD) : $2,666,702,000
2020 R&D spend : $2,215,942,000
2020 Number of Employees : 1,773
Fiscal Year End : 12/31/2020
Key People : Hervé Hoppenot, CEO

Incyte has a hematology and oncology franchise that includes four approved products: Jakafi (ruxolitinib), Monjuvi (tafasitamab-cxix), Pemazyre (pemigatinib) and Iclusig (ponatinib). Jakafi was the first FDA-approved therapeutic to inhibit enzymes called janus associated kinases (JAK), according to Incyte. FDA approved Jakafi in 2011 for the treatment of the rare and life-threatening condition myelofibrosis, followed by later approvals for diseases including polycythemia vera (PV) and steroid-refractory acute graft-versus-host disease. Incyte sells Jakafi inside the United States, while Novartis sells it outside the U.S. under the name Jakavi. –CN